Drug Database
MY

MYJ-1633 (MYJ1633 / MYJ 1633)

✓ Approved

Immunisbio · 细胞治疗 · 细胞治疗

什么是 MYJ-1633?

MYJ-1633 是一种细胞治疗,由Immunisbio研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名MYJ1633, MYJ 1633
公司Immunisbio
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

MYJ-1633 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

相关研究文献

PubMedTherapeutic advances in medical oncology2026-11-18

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small bowel tumor cohort.

Chae Young Kwang YK, Dietrich Eliana E, Patel Sandip P SP, Zalupski Mark M et al.

Checkpoint inhibitors have advanced treatment of many cancers. However, their efficacy in many rare tumor types remains unclear; hence, data in these cancers is an unmet need. This paper presents the results of combination therapy with both anti-CTLA and anti-PD-1 in the small bowel cohort of SWOG S1609 dual anti-CTLA-4 & anti-PD-1 blockade in Rare Tumors (DART). DART is a prospective, open-label, multicenter (>1000 sites opened) phase II clinical trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) in rare tumors. DART was conducted through the SWOG Early Therapeutics and Rare Cancers Committee, supported by NCI, and opened at >1000 sites. The primary endpoints included overall response rate (ORR) (RECIST v1.1), complete response (CR) and partial response (PR). Progression-free survival (PFS), overall survival (OS), stable disease (SD) >6 months, and toxicity were secondary endpoints. Twenty-six patients (evaluable, N = 23) were registered. The duodenum was the primary site in 48% (N = 11). The ORR was 9% (CR, 4%, N = 1 (PFS 252 days); PR, 4%, N = 1 (1633+ days); clinical benefit rate (CBR; includes SD > 6 months/PR/CR), 13%. Six-month PFS was 17%; 6-month OS, 50%. Longest responder is ongoing at 1633+ days. The most common toxicities were fatigue and dyspnea (21.7% each), diarrhea and hypothyroidism (17.4% each), with diarrhea, increased bilirubin, colitis and elevated lipase as the most common grade 3-5 immune-related adverse events. Combination therapy with nivolumab plus low-dose ipilimumab in small bowel tumors resulted in a response rate of 9% in 23 treated patients (CBR 13%), including a CR lasting 8 months and a PR ongoing at >4.5+ years. However, the small sample size underpowers meaningful subgroup analysis. Translational studies are needed to identify biologic characteristics that predict response. ClinicalTrials.gov registry: NCT02834013.

PMID 43047908
阅读全文 →
PubMedBMC infectious diseases2026-11-16

Neurolisteriosis in adults: a case series highlighting clinical and diagnostic challenges and review of Indian literature.

Vijayakumar Divya D, Unnikrishnan Gopikrishnan G, Udit Saraf S, Sebastian Chinnu Liz CL et al.

Neurolisteriosis due to Listeria monocytogenes is uncommon but associated with high morbidity and mortality. Diagnosis is often delayed due to heterogeneous clinical presentations, overlap with non-infectious neurological conditions and limited sensitivity of early diagnostic tests. We conducted a single centre retrospective chart review at a tertiary care teaching hospital between January 2024 to March 2026. Adult patients (≥ 18 years) with microbiologically confirmed neurolisteriosis cases were included. Clinical, radiological, microbiological, treatment, and outcome data were analysed descriptively. Of the 1633 CSF samples analysed, 110 (6.7%) were positive for bacterial meningitis, of which 3 (2.7%) were due to Listeria monocytogenes. The median age of patient was 57 years (range: 30-69) with female predominance. One patient had SLE on immunosuppressive therapy while other two were immunocompetent. The median symptoms duration prior to admission was 1 day with common presenting symptoms headache, fever and altered sensorium. Imaging demonstrated hyperintense meningeal or parenchymal enhancement. CSF revealed neutrophilic pleocytosis, elevated protein, and low glucose. CSF and blood cultures were positive in all cases. Delayed appropriate therapy led to deterioration, but targeted ampicillin-based treatment resulted in favourable outcomes. Neurolisteriosis remains a significant diagnostic challenge due to its variable clinical presentation; therefore, maintaining a high index of suspicion and ensuring early recognition with prompt initiation of ampicillin-based therapy are essential for improving patient outcomes.

PMID 43035675
阅读全文 →
PubMedCancer2026-10-27

Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience.

Bisogno Gianni G, Ferrari Andrea A, Fajardo Raquel Dávila RD, Kelsey Anna A et al.

Survivors of childhood rhabdomyosarcoma (RMS) are at increased risk of second malignant neoplasms (SMNs), influenced by treatment type and genetic predisposition. Recently, the addition of maintenance chemotherapy with low-dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high-risk disease. However, the potential SMN risk from increased cumulative alkylating agent exposure remains unclear. The authors analyzed 1633 patients enrolled in the European RMS 2005 trial. Cumulative incidence of SMN was estimated using competing risk methodology. Outcomes were compared between patients who did and did not receive maintenance chemotherapy. After a median follow-up of 9.3 years (range, 0.6-17.7), 27 patients (1.7%) developed a SMN. Eight had a known cancer predisposition syndrome: Li-Fraumeni syndrome (LFS) in six patients and neurofibromatosis type 1 (NF1) in two patients. Osteosarcoma was the most frequent SMN (n = 6), followed by low-grade glioma (n = 3), hematological malignancies (n = 3), and undifferentiated sarcoma (n = 2). Twenty of 27 patients with SMN received radiotherapy before developing an SMN, including eight who's SMN arose within a previously irradiated field. Three of these eight patients had LFS. The 8-year cumulative incidence of SMN in the entire cohort was 1.3% (95% CI, 0.8-2.0). SMNs occurred in 17 of 1081 patients without maintenance therapy (1.6%) and in nine of 486 patients who received maintenance therapy (1.9%; p = .75). Maintenance chemotherapy was not associated with increased SMN risk. Genetic predisposition was a major contributor to SMN development, supporting risk-adapted survivorship care. Longer follow-up is required to evaluate late-occurring SMNs.

PMID 42944591
阅读全文 →
PubMedPharmaceutics2026-10-27

Drug-Induced CYP2D6 Phenoconversion Among Individuals with a Psychiatric Disorder: Prevalence and Association with Psychological Distress.

Mason Ellen R ER, Ali Mohamed Y MY, Burns Richéal M RM, Shukla Priyank P et al.

Background/Objectives: Phenoconversion extends pharmacogenomics beyond genetic variation by accounting for non-genetic factors that can also dynamically alter metabolism, influence treatment response, adverse effect risk and overall patient outcomes. CYP2D6 phenoconversion is problematic in people with psychiatric conditions due to the high comorbidity and polypharmacy burden in this population and the significant proportion of psychiatric medications that inhibit CYP2D6 metabolism or are directly metabolised by CYP2D6. Our aim was to estimate the prevalence of CYP2D6 phenoconversion, the association with comorbidity and polypharmacy and the impact on mental health outcomes. Methods: Using UK Biobank data, phenoconversion was estimated by applying a standard multiplication factor to genotype-based activity scores according to CYP2D6 inhibitor use, and associations with comorbidity and polypharmacy were assessed. Findings were validated by meta-analysis (PROSPERO, CRD420251177663). Regression analyses assessed the relationship between CYP2D6 phenoconversion and psychological distress, measured using a modified version of the PHQ-4 from UK Biobank. Results: Seventeen percent (n = 5942) of UK Biobank participants with a self-reported psychiatric/psychological disorder (n = 35,338) were estimated to be subject to CYP2D6 phenoconversion. CYP2D6 phenoconverted individuals had higher comorbidity and polypharmacy medications, each p < 0.001. Twelve studies were included in our meta-analysis, producing a pooled prevalence of 17% (n = 7498, 95% CIs:12-24%, I2 = 98%) and 13% (n = 1633, 95% CIs: 11-15%, I2 = 24.2%) in a more homogeneous adult-only subgroup. CYP2D6 phenoconversion was significantly associated with higher modified PHQ-4 scores from UK Biobank (p < 0.001, r = 0.067), with individuals subject to phenoconversion scoring 10% higher (IRR 1.10, 95% CIs: 1.07-1.13) and having 19% greater odds of higher psychological distress scores (modified PHQ-4 score ≥ 6) (OR 1.19, 95% CIs: 1.11-1.28). Conclusions: Overall, CYP2D6 inhibitor use is common in psychiatry, and our findings support the need to consider phenoconversion.

PMID 42942849
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

Association of Anterior Ventricular Aneurysm and D-Dimer with Intracardiac Thrombus in Patients with Acute Myocardial Infarction: A Retrospective Analysis.

Li Bohan B, Huang Xiaorui X, Lian Zizhu Z, Liu Shikang S et al.

Background: Intracardiac thrombus is a clinically important complication of acute myocardial infarction (AMI), particularly in patients with ventricular aneurysm. We examined the contemporaneous associations of anterior ventricular involvement and D-dimer with echocardiographically documented intracardiac thrombus with incomplete chamber-specific localization among hospitalized AMI patients with ventricular aneurysm. Methods: This retrospective analysis included 1684 patients with documented ventricular aneurysm from a final cohort of 17,950 hospitalized AMI patients treated between January 2018 and October 2025. The first D-dimer measurement obtained at our hospital after AMI confirmation was used for D-dimer analyses. Ventricular aneurysm and intracardiac thrombus status were determined from the available echocardiographic documentation during the index hospitalization. Aneurysm locations were coded as linked patient-level, non-mutually exclusive indicators. Logistic regression evaluated anterior involvement; missing model covariates were multiply imputed and regression estimates were pooled using Rubin's rules. Collinearity diagnostics and sensitivity analyses restricted to patients with apical aneurysm, including a complete-case analysis, were performed. Model-performance measures were interpreted as exploratory apparent performance in the development dataset. Results: Intracardiac thrombus was documented in 211 of 1684 patients (12.5%). Anterior involvement was more frequent among patients with thrombus than among those without thrombus (57.3% vs. 45.0%; p < 0.001) and remained associated with thrombus in the primary anatomical and clinical model (OR, 1.63; 95% CI, 1.20-2.21; p = 0.002). D-dimer was available in 1633 patients. On the log2-transformed scale, each doubling of D-dimer was associated with higher odds of echocardiographically documented intracardiac thrombus (adjusted OR, 1.24; 95% CI, 1.14-1.34; p < 0.001). As a complementary descriptive analysis, the observed thrombus proportion increased from 3.63% in Q1 to 22.30% in Q4; compared with Q1, the adjusted ORs were 3.71, 5.22, and 9.50 in Q2, Q3, and Q4, respectively. The combined model had a mean apparent AUC of 0.716, compared with 0.713 for the model containing D-dimer without anterior involvement; the mean absolute increment was approximately 0.003. Conclusions: Among hospitalized patients with AMI and ventricular aneurysm, higher D-dimer levels and anterior ventricular involvement were associated with echocardiographically documented intracardiac thrombus. Chamber-specific localization was incomplete, and these contemporaneous associations do not establish causality or prospective prediction. Anterior involvement provided minimal incremental discrimination beyond D-dimer.

PMID 42941688
阅读全文 →
PubMedClinical neurology and neurosurgery2026-10-25

Operative challenges and functional outcomes of salvage microsurgery in Gamma Knife-failed vestibular schwannoma: A 12-year institutional experience.

Birua Gyani J S GJS, Sadashiva Nishanth N, Thimmarayappa Arun A, Varshini Amrutha A et al.

Vestibular schwannoma (VS) is a benign tumor of the vestibular nerve. In selected cases, Gamma Knife radiosurgery (GKRS) is used due to its minimally invasive nature and reported tumor control rates of approximately 90%. Salvage microsurgery after failed GKRS is uncommon, and its technical difficulty remains debated. Some authors report increased surgical challenges, while others find no significant differences compared to primary microsurgery. This study presents our experience with salvage microsurgery for VS following failed GKRS, focusing on operative challenges and outcomes. This retrospective observational study was conducted at the National Institute of Mental Health and Neurosciences (NIMHANS), India. Between 2012 and 2023, 1633 patients underwent surgery for vestibular schwannoma, including primary and recurrent cases. Among these, 24 patients had previously received GKRS and subsequently required salvage microsurgery. We retrieved clinical, radiological, and operative data from institutional medical records and PACS imaging. GKRS parameters, including tumor volume and radiation dose, were obtained from the GKRS department. Of the 24 patients, eight were operated on for right-sided tumors, and sixteen for left-sided tumors. The mean tumor volume increased from 7.8 cc before GKRS to 19.13 cc at surgery. The median interval from symptom onset to GKRS was 28.91 months, while the median duration from GKRS to surgery was 28.81 months. Central contrast enhancement decreased at six months post-GKRS in 66.7% of cases. The mean operative time was 332.92 min, and the mean blood loss was 570 mL. Tumors were firm in 58.3% of cases and moderately vascular in 75%. The fifth and seventh cranial nerves were identified in 62.5% and 75.0% of cases, respectively. Tumor adherence to the brainstem was observed in 17 cases, while significant arachnoid thickening was present in only four cases. Salvage microsurgery after failed Gamma Knife radiosurgery for vestibular schwannoma is feasible and safe. However, post-radiosurgical tissue changes, such as adherence of the cranial nerves to the tumor and difficulty identifying the cranial nerves, make it technically more demanding than primary microsurgery, resulting in lower rates of gross total resection and a higher incidence of facial nerve morbidity. In this setting, a strategy prioritising maximal safe resection and functional preservation, rather than complete tumour clearance, is recommended.

PMID 42925652
阅读全文 →

注册免费账户还可查看另外 954 篇文献

免费注册查看全部文献 →

了解更多MYJ-1633